- Home
- GCMG vs ANL Comparison
GCMG vs ANL Comparison
Compare GCMG & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | GCMG | ANL |
|---|---|---|
| Founded | 1971 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | |
| Sector | Finance | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 731.1M | 703.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | GCMG | ANL |
|---|---|---|
| Price | $10.86 | $16.37 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $14.33 | ★ $20.00 |
| AVG Volume (30 Days) | 421.9K | ★ 574.1K |
| Earning Date | 05-07-2026 | 04-10-2026 |
| Dividend Yield | ★ 4.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.28 | $36.02 |
| Revenue Next Year | $11.70 | N/A |
| P/E Ratio | $28.21 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.30 | $0.88 |
| 52 Week High | $13.22 | $17.25 |
Technical Indicators
Market Signals| Indicator | GCMG | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 58.51 | 71.10 |
| Support Level | $10.35 | $1.36 |
| Resistance Level | $11.88 | N/A |
| Average True Range (ATR) | 0.32 | 2.46 |
| MACD | 0.16 | 0.60 |
| Stochastic Oscillator | 82.00 | 91.24 |
Price Performance
Historical ComparisonAbout GCMG GCM Grosvenor Inc.
GCM Grosvenor Inc is a world-wide alternative asset management firm. It invests on behalf of clients who seek allocations to alternative investments, such as private equity, infrastructure, real estate, credit, ESG and absolute return strategies. Company invest maximum in Private Equity. The company's offerings include multi-manager portfolios as well as portfolios of direct investments and co-investments.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.